JAMA Network
About the Study: Does the addition of high-dose vitamin D to standard treatment improve progression-free survival in patients with metastatic colorectal cancer? In this multicenter, double-blind phase 3 randomized clinical trial in patients with previously untreated metastatic colorectal cancer, the addition of high-dose vitamin D to standard treatment did not significantly improve progression-free survival compared with standard-dose vitamin D (median progression-free survival, 11.8 months vs 10.3 months, respectively). High-dose vitamin D did not improve progression-free survival in patients with metastatic colorectal cancer.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
